Search Result

Results for "

chronic hepatitis C

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (6) HCV (14) Apoptosis (2) Atg8/LC3 (2) Autophagy (3) Bacterial (1) Bcl-2 Family (1) CDK (2) Claudin (1) COX (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (3) DNA/RNA Synthesis (2) Drug Isomer (1) Endogenous Metabolite (1) ERK (2) Ferroptosis (1) FGFR (1) Glutathione S-transferase (1) HCV Protease (7) HIV (1) HSP (1) IFNAR (1) Interleukin Related (1) JNK (2) Macrophage migration inhibitory factor (MIF) (1) Microtubule/Tubulin (1) MMP (1) mTOR (1) Necroptosis (1) NF-κB (1) P-glycoprotein (3) p38 MAPK (1) p62 (2) PGE synthase (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Infection (28) Inflammation/Immunology (6) Neurological Disease (1)
Oligonucleotides:	CpG ODNs (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-N0249

Saikosaponin C 2 Publications Verification	MMP	Infection Inflammation/Immunology
Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection .

HY-W018791

Bifendate 2 Publications Verification DDB	HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-E70529

Ribonucleoside vanadyl complexes	DNA/RNA Synthesis Bacterial	Infection
Ribonucleoside vanadyl complexes are a class of potent RNase and Taq polymerase inhibitors. Ribonucleoside vanadyl complexes protect RNA during RNA isolation by inhibiting ribonucleases, and also reduce the viability of bacteria and eukaryotic cells by interfering with ribosomal subunit assembly. Ribonucleoside vanadyl complexes block PCR and reverse transcription reactions templated by viral nucleic acids and enhance the effects of antibiotics against Staphylococcus aureus, but do not directly inhibit protein synthesis. Ribonucleoside vanadyl complexes can be effectively removed by phenol-chloroform extraction, thus enabling subsequent PCR analysis. Ribonucleoside vanadyl complexes can be applied in research related to chronic hepatitis C (HCV) and Staphylococcus aureus infection .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-N12586

Pheophytin a	ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease	Infection Neurological Disease Cancer
Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC₅₀=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .

HY-108842

Peginterferon alfa-2b PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg	HIV HCV	Infection Cancer
Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C .

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	FGFR Necroptosis Apoptosis CDK JNK	Inflammation/Immunology
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the *CDK1/Cdc25C* pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-13337

BMS-986094 INX-08189	HCV	Infection
BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC₅₀ of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2’-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-117411A

Coblopasvir dihydrochloride KW-136 dihydrochloride	HCV HCV Protease	Infection
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .

HY-103487

Uprifosbuvir IDX21437; MK-3682	HCV	Infection
Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus .

HY-149308

MKA031	Macrophage migration inhibitory factor (MIF)	Infection
MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC₅₀ value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection .

HY-117411

Coblopasvir KW-136	HCV HCV Protease	Infection Inflammation/Immunology
Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .

HY-I0726

Enantiomer of Sofosbuvir	HCV Drug Isomer	Infection
Enantiomer of Sofosbuvir is an enantiomer of Sofosbuvir, a prescription medicine for the treatment of patients with chronic hepatitis C. There is no biological activity report on enantiomer of Sofosbuvir until now.

HY-14404

MK-1220	HBV HCV Protease	Infection
MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A protease) with a K_i of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC₅₀s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum). MK-1220 can be used for the study of chronic hepatitis C virus infection .

HY-W018791R

Bifendate (Standard) DDB (Standard)	Reference Standards HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-13465A

VCH-916 free base	HCV	Infection
VCH-916 free base is the free base form of VCH-916 (HY-13465). VCH-916 free base is an inhibitor for non-nucleoside type NS5B HCV polymerase .

HY-147358C

(1R,4S)-Yimitasvir diphosphate (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-13655A

Isatoribine	Toll-like Receptor (TLR)	Infection
Isatoribine is a TLR7 agonist. Isatoribine is used in the study of chronic hepatitis C virus (HCV) infection .

HY-I0516

PSI 352707 GS-566500	Endogenous Metabolite	Infection
PSI 352707 (GS-566500) is a sofosbuvir metabolite with activity similar to other antiviral compounds. PSI 352707 showed good safety and tolerability in inhibiting chronic hepatitis C virus infection .

HY-119161

VX-759 VCH-759	DNA/RNA Synthesis HCV HCV Protease	Infection
VX-759 (VCH-759) is an orally active HCV NS5B RNA-dependent RNA polymerase inhibitor. VX-759 is promising for research of chronic hepatitis C .

HY-165069

N-Docosanoyl-D-erythro-sphingosylphosphorylcholine Sphingomyelin (d18:1 C22:0)	Others	Others
N-Docosanoyl-D-erythro-sphingosylphosphorylcholine (Sphingomyelin (d18:1 C22:0)) is a compound that appears in the plasma sphingolipid profile after chronic hepatitis C virus infection. The level of this substance in plasma is associated with hepatic steatosis and may be an independent factor of hepatic steatosis.

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-108839

Peginterferon alfa-2a Ro 25-8310/000	IFNAR	Infection
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection .

HY-182691

Amphihevir	HCV	Infection
Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against HCV genotype 1a and 1b replicons and reduces HCV RNA levels. Amphihevir can be used in the research of chronic hepatitis C .

HY-183260

HBV-IN-57	HBV Cytochrome P450	Infection
HBV-IN-57 is an orally active HBV inhibitor with pan-genotypic efficacy against HBV genotypes B/C. HBV-IN-57 inhibits HBV DNA replication and HBV capsid assembly. HBV-IN-57 can be used for the research of chronic hepatitis B .

HY-17619

Ravidasvir PPI-668	HCV	Infection
Ravidasvir (PPI-668) is an orally active pan-genotypic NS5A inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC₅₀ values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection .

Cat. No.	상품명

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	상품명	Target	Research Area	Image